Intelligent Bio Solutions Inc. (INBS) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-K for FY2026, filed Aug 19, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the INBS SEC filings page.
Intelligent Bio Solutions Inc. (INBS) reported $4.2M in revenue for fiscal year 2026, up 38.1% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue is scaling, but gross profit still funds only a fraction of operating costs, leaving financing central to the model.
From FY2024 to FY2026, gross margin expanded from45.8% to48.6% while operating margin remained deeply negative at-299.1% ; the bottleneck is converting gross profit into an operating surplus, not generating gross profit.
FY2026’s net loss of
FY2026 financing cash flow was a
Financial Health Signals
Scored against emerging companies for FY2026. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Intelligent Bio Solutions Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Intelligent Bio Solutions Inc. held $4.0M in cash, cash equivalents and investments at the end of fiscal year 2026, and its operations used $11.9M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Intelligent Bio Solutions Inc. scores 16/100 among other emerging companies.
Intelligent Bio Solutions Inc. had 3M shares outstanding at the end of fiscal year 2026. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Intelligent Bio Solutions Inc. scores 80/100 among other emerging companies.
Not available for Intelligent Bio Solutions Inc., and counted as zero in the overall score.
Intelligent Bio Solutions Inc. reported revenue of $4.2M in fiscal year 2026, against $3.1M in fiscal year 2025. Revenue Progress ranks emerging companies on the three-year path of that line, and Intelligent Bio Solutions Inc. scores 62/100 among other emerging companies.
Intelligent Bio Solutions Inc.'s operations used $11.9M of cash in fiscal year 2026, against $9.7M used in fiscal year 2025. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Intelligent Bio Solutions Inc. scores 34/100 among other emerging companies.
Intelligent Bio Solutions Inc.'s cash, cash equivalents and investments came to $4.0M at the end of fiscal year 2026, against $6.7M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Intelligent Bio Solutions Inc. scores 47/100 among other emerging companies.
Intelligent Bio Solutions Inc. scores -11.24, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($5.1M) relative to total liabilities ($6.7M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Intelligent Bio Solutions Inc. passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
Intelligent Bio Solutions Inc. reported a net loss of $12.4M while operations used $11.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Intelligent Bio Solutions Inc. reported an operating loss of $12.6M against $11K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Intelligent Bio Solutions Inc. generated $1.1M in revenue in Q4 2026. This represents an increase of 178.9% from the same quarter a year earlier. Against the prior quarter it is up 8.0%.
Intelligent Bio Solutions Inc.'s EBITDA was -$3.7M in Q4 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 22.7% from the same quarter a year earlier. Against the prior quarter it is down 39.0%.
Intelligent Bio Solutions Inc. reported -$3.9M in net income in Q4 2026. This represents a decrease of 26.5% from the same quarter a year earlier. Against the prior quarter it is down 36.5%.
Intelligent Bio Solutions Inc. earned -$0.90 per diluted share (EPS) in Q4 2026.
Cash & Balance Sheet
Intelligent Bio Solutions Inc. recorded an outflow of $3.2M in free cash flow in Q4 2026, representing a cash shortfall after capex. Against the prior quarter it is up 26.7%.
Intelligent Bio Solutions Inc. held $4.0M in cash as of Q4 2026; long-term debt is not reported for that period.
Not reported for Q4 2026.
Margins & Returns
Intelligent Bio Solutions Inc.'s gross margin was 46.8% in Q4 2026, indicating the percentage of revenue retained after direct costs. This is up 70.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 3.6 percentage points.
Intelligent Bio Solutions Inc.'s ROE was -70.9% in Q4 2026, measuring profit generated per dollar of shareholder equity. This is up 32.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 39.0 percentage points.
Not shown for Q4 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q4 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Intelligent Bio Solutions Inc. reported no capital expenditure in Q4 2026. Against the prior quarter it is down 100.0%.
Not reported for Q4 2026.
Not reported for Q4 2026.
INBS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1M+178.9% | $1.1M+17.6% | $897K+21.0% | $1.1M+11.4% | $411K+7.9% | $902K-0.6% | $741K-19.2% | $998K+10.2% |
| Cost of Revenue | $609K+19.9% | $525K+35.6% | $437K+13.7% | $594K+12.9% | $508K+679.4% | $387K-40.0% | $384K-31.9% | $525K-6.8% |
| Gross Profit | $537K+650.6% | $535K+56.8% | $460K+106.1% | $518K+49.4% | -$97K-112.0% | $341K+91.3% | $223K+12.0% | $347K+49.3% |
| SG&A Expenses | $3.0M+11.0% | $2.5M+1.8% | $2.3M+29.2% | $2.7M+36.5% | $2.7M+2.8% | $2.4M-0.5% | $1.8M+6.1% | $1.9M-20.7% |
| Operating Income | -$4.0M-28.7% | -$2.9M-15.1% | -$2.6M-16.4% | -$3.0M-10.1% | -$3.1M-11.3% | -$2.6M+13.3% | -$2.3M-13.7% | -$2.7M-7.9% |
| EBITDA | -$3.7M-22.7% | -$2.7M-17.6% | -$2.4M-20.1% | -$2.7M-10.4% | -$3.0M-11.6% | -$2.3M+14.3% | -$2.0M-15.2% | -$2.5M-9.0% |
| Interest Expense | -$54K-208.0% | $4K-46.4% | $56K+316.3% | $4K-82.5% | -$17K-131.9% | $8K-81.4% | $14K-58.4% | $22K-40.4% |
| Net Income | -$3.9M-26.5% | -$2.9M-12.5% | -$2.7M-19.0% | -$3.0M-11.1% | -$3.1M-11.0% | -$2.5M+14.6% | -$2.2M-14.2% | -$2.7M-10.7% |
| EPS (Basic) | -$0.90-119.5% | -$1.80+59.2% | -$2.82+43.1% | -$0.35+50.0% | -$0.41-257.7% | -$4.41-208.4% | -$4.96-139.6% | -$0.70+94.4% |
| EPS (Diluted) | -$0.90 | -$1.80 | -$2.82 | -$0.35 | -$0.41 | -$4.41 | -$4.96 | -$0.70 |
| Diluted Shares (Avg) | N/A | 2M | 950,829 | 9M | N/A | 577,191 | 453,582 | 4M |
Not reported in any period shown, so not listed: R&D Expenses, Income Tax.
INBS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $11.9M+44.8% | $14.9M+55.1% | $17.7M+103.3% | $10.0M-14.4% | $8.2M-40.1% | $9.6M-43.7% | $8.7M-1.6% | $11.7M+34.8% |
| Current Assets | $7.1M+71.5% | $9.7M+90.9% | $12.2M+199.8% | $4.5M-30.8% | $4.1M-51.5% | $5.1M-55.7% | $4.1M+37.9% | $6.5M+140.7% |
| Cash & Equivalents | $4.0M+291.4% | $6.9M+144.5% | $740K-67.0% | $1.7M-58.4% | $1.0M-83.8% | $2.8M-70.1% | $2.2M+100.4% | $4.0M+2040.2% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $419K-34.1% | $597K-12.6% | $590K-15.8% | $628K-15.0% | $635K-18.3% | $683K-22.1% | $701K-25.6% | $739K-23.4% |
| Accounts Receivable | $848K+42.7% | $878K+71.9% | $457K+71.6% | $718K+24.1% | $595K+38.4% | $511K+18.4% | $266K+1.2% | $579K+2.0% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $6.7M+22.4% | $6.1M+31.7% | $6.8M+50.9% | $6.6M+14.5% | $5.4M-2.9% | $4.6M-23.2% | $4.5M-21.0% | $5.8M-22.6% |
| Current Liabilities | $4.9M-7.9% | $4.6M+1.0% | $5.1M+16.5% | $5.1M-10.9% | $5.4M-1.8% | $4.6M-20.0% | $4.4M-15.1% | $5.7M-17.0% |
| Non-Current Liabilities | $1.7M+1927.9% | $1.5M+1864.5% | $1.6M+2002.3% | $1.5M+1483.5% | $85K-41.4% | $76K-77.2% | $78K-84.1% | $98K-84.2% |
| Total Equity | $5.5M+83.9% | $9.0M+75.3% | $11.1M+154.1% | $3.6M-40.7% | $3.0M-64.0% | $5.1M-54.1% | $4.4M+33.1% | $6.1M+350.3% |
| Retained Earnings | -$75.0M-19.9% | -$71.1M-19.5% | -$68.2M-19.8% | -$65.5M-19.9% | -$62.5M-20.3% | -$59.4M-20.9% | -$56.9M-23.2% | -$54.6M-23.6% |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
INBS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.2M-44.0% | -$4.3M-57.2% | -$1.6M+32.6% | -$2.8M-19.3% | -$2.2M+24.9% | -$2.8M-12.6% | -$2.3M+19.0% | -$2.4M-82.0% |
| Depreciation & Amortization | $288K+137.5% | $290K-3.8% | $282K-7.6% | $258K+6.7% | $121K-46.7% | $302K-5.3% | $305K+5.1% | $242K-2.4% |
| Stock-Based Compensation | N/A | $12K | N/A | $12K-94.1% | N/A | $0-100.0% | N/A | $202K |
| Capital Expenditures | $0 | -$13K | $68K | $70K | N/A | N/A | N/A | N/A |
| Free Cash Flow | -$3.2M | -$4.3M | -$1.6M | -$2.9M | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $0+100.0% | $13K+189.7% | -$28K | -$70K | -$209K-24.6% | -$14K-663.9% | N/A | N/A |
| Financing Cash Flow | $312K-48.2% | $10.4M+214.3% | $675K+6.8% | $3.6M+8282.0% | $602K+11230.6% | $3.3M-69.2% | $632K | $42K |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
INBS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 46.8%+70.6pp | 50.5%+12.6pp | 51.3%+21.2pp | 46.6%+11.9pp | -23.7% | 37.8%+18.2pp | 30.1%+8.4pp | 34.7%+9.1pp |
| Operating Margin | -351.3% | -277.8% | -293.9% | -269.8% | -761.6% | -283.8% | -305.5% | -273.0% |
| Net Margin | -341.0% | -269.9% | -298.6% | -268.3% | -752.1% | -281.9% | -303.5% | -269.0% |
| Return on Equity | -70.9%+32.2pp | -31.9%+17.8pp | -24.1%+27.4pp | -82.4%-38.4pp | -103.1%-69.7pp | -49.7%-23.0pp | -51.5%+8.5pp | -44.0%+134.9pp |
| Return on Assets | -32.7%+4.7pp | -19.3%+7.3pp | -15.2%+10.7pp | -29.7%-6.8pp | -37.5%-17.3pp | -26.5%-9.1pp | -25.9%-3.6pp | -22.9%+5.0pp |
| Current Ratio | 1.44+0.7x | 2.11+1.0x | 2.37+1.5x | 0.89-0.3x | 0.77-0.8x | 1.12-0.9x | 0.92+0.4x | 1.14+0.7x |
| Debt-to-Equity | 1.21-0.6x | 0.68-0.2x | 0.61-0.4x | 1.83+0.9x | 1.81+1.1x | 0.91+0.8x | 1.03-0.7x | 0.95-4.6x |
| Asset Turnover | 0.100.0x | 0.070.0x | 0.050.0x | 0.110.0x | 0.050.0x | 0.090.0x | 0.090.0x | 0.090.0x |
| FCF Margin | -277.7% | -409.4% | -182.4% | -262.4% | N/A | N/A | N/A | N/A |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Intelligent Bio Solutions Inc. INBS | FY2026 | $4.2M | -$12.4M | N/A | $5.1M | 40/100 |
| Ainos, Inc. AIMD | FY2025 | $124K | -$14.8M | N/A | $8.9M | — |
| Nexalin Technology, Inc. NXL | FY2025 | $302K | -$8.2M | N/A | $3.8M | — |
| ALLURION TECHNOLOGIES ALUR | FY2025 | $15.2M | -$28.8M | N/A | $10.0M | — |
| enVVeno Medical Corporation NVNO | FY2025 | N/A | -$19.5M | N/A | $6.1M | — |
| SiNtx Technologies, Inc. SINT | FY2025 | $1.0M | -$10.4M | N/A | $14.1M | 51/100 |
Where Intelligent Bio Solutions Inc. Ranks
Frequently Asked Questions
What is Intelligent Bio Solutions Inc.'s annual revenue?
Intelligent Bio Solutions Inc. (INBS) reported $4.2M in total revenue for fiscal year 2026. This represents a 38.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Intelligent Bio Solutions Inc.'s revenue growing?
Intelligent Bio Solutions Inc. (INBS) revenue grew by 38.1% year-over-year, from $3.1M to $4.2M in fiscal year 2026.
Is Intelligent Bio Solutions Inc. profitable?
No, Intelligent Bio Solutions Inc. (INBS) reported a net income of -$12.4M in fiscal year 2026.
What is Intelligent Bio Solutions Inc.'s EBITDA?
Intelligent Bio Solutions Inc. (INBS) had EBITDA of -$11.4M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
What is Intelligent Bio Solutions Inc.'s gross margin?
Intelligent Bio Solutions Inc. (INBS) had a gross margin of 48.6% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.
What is Intelligent Bio Solutions Inc.'s return on equity (ROE)?
Intelligent Bio Solutions Inc. (INBS) has a return on equity of -225.6% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
What is Intelligent Bio Solutions Inc.'s free cash flow?
Intelligent Bio Solutions Inc. (INBS) recorded an outflow of $12.1M in free cash flow during fiscal year 2026. This represents a -21.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Intelligent Bio Solutions Inc.'s operating cash flow?
Intelligent Bio Solutions Inc. (INBS) recorded an outflow of $11.9M in operating cash flow during fiscal year 2026, representing cash used by core business activities.
What are Intelligent Bio Solutions Inc.'s total assets?
Intelligent Bio Solutions Inc. (INBS) had $11.9M in total assets as of fiscal year 2026, including both current and long-term assets.
What are Intelligent Bio Solutions Inc.'s capital expenditures?
Intelligent Bio Solutions Inc. (INBS) invested $126K in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.
What is Intelligent Bio Solutions Inc.'s current ratio?
Intelligent Bio Solutions Inc. (INBS) had a current ratio of 1.44 as of fiscal year 2026, which is considered adequate.
What is Intelligent Bio Solutions Inc.'s debt-to-equity ratio?
Intelligent Bio Solutions Inc. (INBS) had a debt-to-equity ratio of 1.21 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Intelligent Bio Solutions Inc.'s return on assets (ROA)?
Intelligent Bio Solutions Inc. (INBS) had a return on assets of -104.1% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
What is Intelligent Bio Solutions Inc.'s P/E ratio?
Intelligent Bio Solutions Inc. (INBS) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2026). The market capitalization is $5.1M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Intelligent Bio Solutions Inc.'s price-to-sales ratio?
Intelligent Bio Solutions Inc. (INBS) trades at 1.2x sales, its market capitalization divided by revenue of $4.2M revenue, FY2026. The market capitalization is $5.1M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Intelligent Bio Solutions Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2026, Intelligent Bio Solutions Inc. (INBS) held $4.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $11.9M over that year. Dividing the one by the other, the reported balance equals about 4 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Intelligent Bio Solutions Inc.'s Altman Z-Score?
Intelligent Bio Solutions Inc. (INBS) has an Altman Z-Score of -11.24, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Intelligent Bio Solutions Inc.'s Piotroski F-Score?
Intelligent Bio Solutions Inc. (INBS) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Intelligent Bio Solutions Inc.'s earnings high quality?
Intelligent Bio Solutions Inc. (INBS) reported a net loss of $12.4M while operations used $11.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Intelligent Bio Solutions Inc. cover its interest payments?
Intelligent Bio Solutions Inc. (INBS) reported an operating loss of $12.6M against $11K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Intelligent Bio Solutions Inc.?
Intelligent Bio Solutions Inc. (INBS) scores 40 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.